Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GAMB -15.9% (also to acquire Spotlight.Vegas; expands share buyback authorization; also files for $200 mln shelf offering; also files for offering by selling shareholders), AMAT -13.6%, GLOB -11.6%, SNDK -10.5%, SY -7.6%, STRZ -6.2%, QFIN -4.5%, TMC -3.3%, FLO -1%
Other news:
- KLAC -5.5% (in sympathy with weak AMAT earnings)
- NUTX -5.2% (to delay 10-Q filing)
- LRCX -5% (in sympathy with weak AMAT earnings)
- AKRO -4.6% (Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH)
- UTL -4.4% (prices offering of 1,393,355 shares of common stock at $46.65 per share)
- CRWV -2.6% (IPO lock-up period expires)
- HIMS -2.5% (under investigation by FTC, according to Bloomberg)
- ASML -2.4% (in sympathy with weak AMAT earnings)
- CRCL -2.2% (prices offering of 10.0 mln shares of common stock at $130.00 per share)